November 26, 2011 -- According to reports, China will invest $1.7 trillion over the next five years in five strategic industries, including biotechnology, though the program has never been officially confirmed; Fosun Pharma received permission to offer up to $470 million of corporate bonds; Kunming Pharma will partner with Heilongjiang ZBD Pharma to develop a TCM used for blood disorders; Bayer has found a second life in China for a 17-year-old diabetes drug, Glucobay; Lilly remains worried about IP theft in China, even though the company is upping its investment in the PRC; and Tasly Pharma chose ICON to conduct a global Phase III trial of Tasly’s oral TCM treatment for angina. More details….
Stock Symbol: (SHA: 600196) (SHA: 600422) (XETRA: BAY) (NYSE: LLY) (SHA: 600535) (NSDQ: ICLR)
